- Pipeline -

Advancing Drug Discovery Research



As bacterial resistance to antimicrobials continues to evolve by adapting to novel mechanisms of action, all antibiotics are under tremendous threat and will eventually become ineffective with usage over time. In continuation of our relentless efforts to address the problems associated with Antimicrobial Resistance (AMR), NAEJA-RGM is always exploring new programs.

Currently under exploration in the early stages of the discovery process are two new antibiotic programs as yet to be formally announced.

Patented Projects Currently In Development



As the incidence of infections with multidrug-resistant (MDR) Gram-negative pathogens continues to grow, the list of therapeutic options available for effective treatment is dwindling.In February 2017, the World Health Organization published a list of “priority pathogens” in the global fight against this growing threat. NAEJA-RGM has developed a new series of compounds showing exciting preliminary results against drug-resistant Gram-positive and Gram-negative bacteria. Currently these lead compounds of the new series are in pre-clinical developmental stage.The provisional patent was filed by NAEJA Pharmaceutical Inc. in December 2015; the full patent was filed by NAEJA-RGM Pharmaceuticals Inc. in December 2016.